The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells

Endocrinology

Volumn 152, Issue 11, 2011, Pages 4062-4071

  Kinet, Virginie ^a   Castermans, Karolien ^a   Herkenne, Stéphanie ^a   Maillard, Catherine ^a   Blacher, Silvia ^a   Lion, Michelle ^a   Noël, Agnès ^a   Martial, Joseph A ^a   Struman, Ingrid ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIC PROTEIN; PROLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE;

ANGIOSTATIC PROTEINS; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HUMANS; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROLACTIN;

EID: 80054894378     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1081     Document Type: Article

References (51)

1. Lee H, Struman I, Clapp C, Martial J, Weiner RI 1998 Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139:3696-3703 (Pubitemid 28512247)
2. Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI 2000 The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 14:1536-1549
3. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA 1999 Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 96:1246-1251 (Pubitemid 29098436)
4. Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I 2005 The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol 19:1932-1942 (Pubitemid 41007903)
5. Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I 2003 The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-κB. Mol Endocrinol 17:1815-1823 (Pubitemid 37072297)
6. Piwnica D, Fernandez I, Binart N, Touraine P, Kelly PA, Goffin V 2006 A new mechanism for prolactin processing into 16K PRL by secreted cathepsin D. Mol Endocrinol 20:3263-3278 (Pubitemid 44833570)
7. D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI 1999 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 13:692-704 (Pubitemid 30645323)
8. D'Angelo G, Struman I, Martial J, Weiner RI 1995 Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92:6374-6378
9. Ferrara N, Clapp C, Weiner R 1991 The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129:896-900
10. Lee SH, Kunz J, Lin SH, Yu-Lee LY 2007 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res 67:11045-11053 (Pubitemid 350145935)
11. Clapp C, Weiner RI 1992 A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130:1380-1386
12. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H 2007 A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589-600 (Pubitemid 46206082)
13. González C, Parra A, Ramírez-Peredo J, García C, Rivera JC, Macotela Y, Aranda J, Lemini M, Arias J, Ibargü engoitia F, de la Escalera GM, Clapp C 2007 Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest 87:1009-1017
14. Erdmann S, Ricken A, Merkwitz C, Struman I, Castino R, Hummitzsch K, Gaunitz F, Isidoro C, Martial J, Spanel-Borowski K 2007 The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. Am J Physiol Endocrinol Metab 293:E1365-E1377 (Pubitemid 350106606)
15. Carmeliet P, Jain RK 2000 Angiogenesis in cancer and other diseases. Nature 407:249-257
16. Bentzien F, Struman I, Martini JF, Martial J, Weiner R 2001 Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 61:7356-7362 (Pubitemid 32946536)
17. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH 2003 Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63:386-393 (Pubitemid 36152497)
18. Kinet V, Nguyen NQ, Sabatel C, Blacher S, Noël A, Martial JA, Struman I 2009 Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Lett 284:222-228
19. Nguyen NQ, Cornet A, Blacher S, Tabruyn SP, Foidart JM, Noël A, Martial JA, Struman I 2007 Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol Ther 15:2094-2100
20. Cueni LN, Detmar M 2008 The lymphatic system in health and disease. Lymphat Res Biol 6:109-122
21. Swartz MA, Skobe M 2001 Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 55:92-99 (Pubitemid 32988910)
22. Van Trappen PO, Pepper MS 2002 Lymphatic dissemination of tumour cells and the formation of micrometastases. Lancet Oncol 3:44-52 (Pubitemid 34121145)
23. Hirakawa S 2009 From tumor lymphangiogenesis to lymphvascular niche. Cancer Sci 100:983-989
24. Sleeman JP, Thiele W 2009 Tumor metastasis and the lymphatic vasculature. Int J Cancer 125:2747-2756
25. Chambers AF, Groom AC, MacDonald IC 2002 Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572 (Pubitemid 37328923)
26. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K 2002 Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2:573-583 (Pubitemid 37328924)
27. Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, Martial JA, Weiner R, Struman I, Grant MB 2004 Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 45:2413-2419 (Pubitemid 38902617)
28. Deroanne CF, Colige AC, Nusgens BV, Lapiere CM 1996 Modulation of expression and assembly of vinculin during in vitro fibrillar collagen-induced angiogenesis and its reversal. Exp Cell Res 224:215-223 (Pubitemid 26140555)
29. Dunworth WP, Fritz-Six KL, Caron KM 2008 Adrenomedullin stabilizes the lymphatic endothelial barrier in vitro and in vivo. Peptides 29:2243-2249 (Pubitemid 50326969)
30. Mikhaylova M, Mori N, Wildes FB, Walczak P, Gimi B, Bhujwalla ZM 2008 Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia 10:380-389
31. Liang CC, Park AY, Guan JL 2007 In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329-333 (Pubitemid 47040047)
32. Harrell MI, Iritani BM, Ruddell A 2007 Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 170:774-786 (Pubitemid 47339411)
33. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, Inaba K, Minato N, Oshima M, Taketo MM 2004 Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64:4010-4017 (Pubitemid 38697317)
34. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST 2001 Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93:1638-1643 (Pubitemid 33094871)
35. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI 1993 The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133:1292-1299 (Pubitemid 23267784)
36. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M 2008 Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14:5459-5465
37. Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, Hess-Stumpp H, Foekens JA, Setyono-Han B, Wood J, Hynes NE 2008 Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics. Cancer Res 68:1581-1592 (Pubitemid 351346868)
38. Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G 2009 Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol Cancer Ther 8:55-63
39. Brideau G, Mäkinen MJ, Elamaa H, Tu H, Nilsson G, Alitalo K, Pihlajaniemi T, Heljasvaara R 2007 Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67:11528-11535
40. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S 2005 Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 22:31-38 (Pubitemid 41185859)
41. Heishi T, Hosaka T, Suzuki Y, Miyashita H, Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y, Takakura T, Hojo K, Matsumoto M, Yamauchi C, Ohta H, Sonoda H, Sato Y 2010 Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol 176:1950-1958
42. Shao XJ, Chi XY 2005 Influence of angiostatin and thalidomide on lymphangiogenesis. Lymphology 38:146-155 (Pubitemid 41609631)
43. Hawighorst T, Oura H, Streit M, Janes L, Nguyen L, Brown LF, Oliver G, Jackson DG, Detmar M 2002 Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 21:7945-7956 (Pubitemid 35430606)
44. Ichise T, Yoshida N, Ichise H 2010 H-, N- and Kras cooperatively regulate lymphatic vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice. Development 137:1003-1013
45. Gonzalez C, Corbacho AM, Eiserich JP, Garcia C, Lopez-Barrera F, Morales-Tlalpan V, Barajas-Espinosa A, Diaz-Muñoz M, Rubio R, Lin SH, Martinez de la Escalera G, Clapp C 2004 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145:5714-5722 (Pubitemid 39564613)
46. Lee SH, Nishino M, Mazumdar T, Garcia GE, Galfione M, Lee FL, Lee CL, Liang A, Kim J, Feng L, Eissa NT, Lin SH, Yu-Lee LY 2005 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway. Cancer Res 65:7984-7992 (Pubitemid 41297278)
47. Lahdenranta J, Hagendoorn J, Padera TP, Hoshida T, Nelson G, Kashiwagi S, Jain RK, Fukumura D 2009 Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 69:2801-2808
48. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH 2008 Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122-136
49. Bruyère F, Melen-Lamalle L, Blacher S, Detry B, Masset A, Lecomte J, Lambert V, Maillard C, Hoyer-Hansen G, Lund LR, Foidart JM, Noël A 2010 Does plasminogen activator inhibitor-1 drive lymphangiogenesis? PLoS One 5:e9653
50. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS 2009 Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239
51. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231